Education
About Us
Working with TipRanks
Follow Us
Korro Bio (KRRO)
NASDAQ:KRRO
KRRO Stock Chart & Stats
$9.00
-$1.03(-2.68%)
At close: 4:00 PM EST
$9.00
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $55.89
Previous CloseN/A
Volume28.02K
Average Volume (3M)734.66K
Market Cap
$84.76M
Enterprise Value$400.95M
Total Cash (Recent Filing)$93.48M
Total Debt (Recent Filing)$44.67M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Mar 31, 2026EPS Estimate
-2.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding9,417,295
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.12
Price to Sales (P/S)149.54
P/FCF Ratio-4.36
Enterprise Value/Market Cap4.73
Enterprise Value/Revenue54.40
Enterprise Value/Gross Profit54.40
Enterprise Value/Ebitda-4.53
Forecast
1Y Price Target
$25.75Price Target Upside186.11% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Development Candidate NominationAnalyst notes Korro's pivot to GalNAc delivery with a planned development candidate nomination, creating a clear program milestone that could re-rate the stock if subsequent data support the approach.
Pipeline DiversificationA second development candidate planned for a rare metabolic disorder indicates pipeline diversification that could provide additional value drivers beyond the lead AATD program.
Safety Profile In Healthy VolunteersClinical updates report more than 80% of planned healthy volunteers dosed in the KRRO-110 trial with no serious adverse events or dose-limiting toxicities observed, supporting a favorable safety narrative for future RNA editing candidates.
Bears Say
Efficacy Failure In AATDKRRO-110 failed to raise functional AAT to target therapeutic levels after a single administration in AATD patients, representing a setback for proof-of-concept and commercial potential in the program.
Financial And Operational StrainA 34% workforce reduction coupled with austerity measures and an extended cash runway signals capital constraints that may increase dilution and execution risk across the pipeline.
Strategic Pivot And Competitive DelayAbandoning the current KRRO-110 formulation and switching from LNP to GalNAc conjugation places the company behind competitors on timelines and raises concerns about differentiation in delivery strategy.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $84.76M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is Mar 31, 2026 which is in 74 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on Nov 12, 2025. The company reported -$1.92 earnings per share for the quarter, beating the consensus estimate of -$2.594 by $0.674.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -2.03.
How many shares outstanding does Korro Bio have?
Korro Bio has 9,417,295 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$1.92 in its last earnings report, beating expectations of -$2.594. Following the earnings report the stock price went down -79.313%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$25.75 (186.11% Upside)
$25.75 (186.11% Upside)
Hedge Fund Trend
Increased
By 91.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-88.72%
12-Months-Change
Fundamentals
Return on Equity
-63.46%
Trailing 12-Months
Asset Growth
-33.67%
Trailing 12-Months
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
KRRO Stock 12 Month Forecast
Average Price Target
$25.75
▲(186.11% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―